<DOC>
	<DOCNO>NCT00822523</DOCNO>
	<brief_summary>The purpose feasibility study determine temporary weakness small foot muscle cause local injection botulinum toxin muscle measure strain gauge addition previously know valid measurement via nerve conduction study surface electromyogram .</brief_summary>
	<brief_title>Assessment Effect Botulinum Toxin Extensor Digitorum Brevis Via Strain Gauge Nerve Conduction Studies</brief_title>
	<detailed_description>Purpose/Hypothesis : Verify validity reliability strain gauge assessment strength extensor digitorum brevis ( EDB ) muscle compare compound muscle action potential ( CMAP ) size EDB surface electromyography ( SEMG ) data EDB injection botulinum toxin EDB 1 . Primary Outcome Measure : Change measure strength ( use strain gauge ) dorsiflexion digits 3 4 ( `` strength EDB '' ) vs. botulinum toxin injection EDB 2 . Secondary Outcome Measures : 1 . Change CMAP ( standard reference electrode location `` inactive '' reference electrode location ) EDB vs. botulinum toxin injection EDB ; 2 . Change SEMG parameter EDB , tibialis anterior ( TA ) , extensor digitorum longus ( EDL ) vs. botulinum toxin injection EDB STUDY DESIGN : 1 . Overview : Single intramuscular injection botulinum toxin placebo ( placebo BOTOX 2 unit BOTOX 20 unit , total volume 0.1 ml ) intramuscular right EDB Day 0 . Strain gauge data SEMG data TA EDL obtain evaluation time : Baseline ( 3 separate time prior Day 0 least 5 separate training session strain gauge ) ; Day 1 ; Day 2 ; Day 4 ( anticipated rapid change ) ; Day 14 ( +/-1 day ) ( clinical nadir ) ; Day 21 ( +/-1 day ) ( another day clinical nadir ) ; Month 4 ( clinical recovery effect BOTOX occur ) ; CMAP &amp; SEMG data EDB obtain Baseline ; Day 4 ( close nadir CAMP ) ; Day 14 ( nadir CAMP ) and/or Day 21 ( nadir CAMP ) ; Month 4 ( clinical recovery effect BOTOX occur CMAP recover ) . 2 . Protocol : Single-center , Double-Blind , Randomized , Pilot Trial Total Sample Size : 12-15 Treatment Groups : BOTOX Single Dose 20 unit IM EDB 0.1 ml BOTOX Single Dose 2 unit IM EDB 0.1 ml Placebo ( Saline ) Single Dose IM EDB 0.1 ml Estimated Time Enroll : 0-3 month Estimated Study Duration : 4-6 month</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Normal , healthy , male female subject , 18 54 year age . Written inform consent obtain . Females childbearing potential negative urine pregnancy test agree use reliable form contraception study . Ability follow study instruction likely complete require visit . Written authorization Use Release Health Research Study Information obtain . Abnormality focus history examination include presence foot deformity . Abnormal ( determine investigator ) screen nerve conduction study low limb . Identification anomalous innervation right EDB via screen nerve conduction study . The subject foot adequately fit modified anklefoot orthosis use strain gauge . The subject foot anatomic bone landmarks adequately identify . Body mass index ( BMI ) great 30 . History significant ( determined investigator ) low limb injury low limb surgery Any uncontrolled clinically significant medical condition . Known allergy sensitivity component study medication . Females positive pregnancy test , breastfeeding , plan pregnancy study , think may pregnant start study , female childbearing potential unable unwilling use reliable form contraception study . Concurrent participation another investigational drug device study participation within 3 month prior study . Treatment botulinum toxin serotype prior enrollment study prior clinical botulism . Any medical condition may put subject increase risk exposure BOTOX include diagnose myasthenia gravis , LambertEaton myasthenic syndrome , amyotrophic lateral sclerosis , disorder might interfere neuromuscular function . Evidence alcohol abuse , drug abuse , relevant neuropsychiatric condition . Infection skin disorder anticipate injection site . Any condition situation , investigator 's opinion , may put subject significant risk , confound study result ( e.g . variable strength serial test screen examination ; foot , toe , ankle pain may limit full participation muscle strength test ) , interfere significantly subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>